Ruiyi Xulian Secures Nearly 100 Million Yuan in Pre-A+ Financing as Its Implantable Bidirectional Brain-Computer Interface Makes Headway
2 day ago / Read about 0 minute
Author:小编   

Suzhou Ruiyi Xulian Medical Technology, an innovative medical device company specializing in brain-computer interfaces and neuromodulation, has recently closed a Pre-A+ financing round worth nearly 100 million yuan. The round was co-led by Puhua Capital and Furon Investment, with participation from Songhe Capital and Beigong Investment, and Xingqiao Capital acting as exclusive financial advisor. The proceeds will be used to advance the company's core product—a brain-spine interface—into clinical trials, support mass production of its modular implantable bidirectional brain-computer interface platform, and expand clinical research into additional indications such as speech decoding, visual reconstruction, and depression. The company has established a full-stack, self-developed system spanning multiple links of the value chain, adopts a modular design and a "one platform, multiple applications" product strategy, and targets indications with rigid demand such as spinal cord injury and post-stroke sequelae. Several of its non-invasive products have already achieved commercial scale-up. Investors have expressed confidence in the company's technical approach and execution capability and will continue to support its growth.